Investigational New Drugs

, Volume 29, Issue 4, pp 574–582 | Cite as

LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin

  • Jian-Jun Gao
  • Zu-Hua Gao
  • Cui-Rong Zhao
  • Yi Yuan
  • Shu-Xiang Cui
  • Xiao-Fan Zhang
  • Yan-Na Cheng
  • Wen-Fang Xu
  • Wei Tang
  • Xian-Jun QuEmail author


LYP is a bestatin dimethylaminoethyl ester which inhibits aminopeptidase N (APN/CD13). Our goal in this study was to evaluate LYP as a candidate compound for cancer treatment, beginning by studying its inhibitory effects on tumors and then comparing it to bestatin. Experiments were performed on human ovarian carcinoma (OVCA) ES-2 and SKOV-3 cell lines, which have high and low levels of APN/CD13 respectively. LYP effectively inhibited ES-2 cell growth as estimated by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and the trypan blue dye-exclusion test. LYP significantly suppressed APN/CD13 activity on the surface of ES-2 cells as measured by quantifying the enzymatic cleavage of the substrate L-leucine-p-nitroanilide. The inhibitory effects of LYP were greater than those of bestatin at the same concentrations. In contrast, LYP was a weak inhibitor of SKOV-3 cell growth, suggesting that LYP may inhibit ES-2 cell growth via suppression of APN/CD13. Inhibition of APN/CD13 expression was also demonstrated with immunofluorescent flow cytometry and Western blot analysis. Inhibitory effects of LYP were confirmed by using a mouse model in which LYP delayed the growth of ES-2 xenografts in mice after 2 weeks of LYP injections. Inhibition of APN/CD13 expression was demonstrated in the ES-2 xenografts using Western blot analysis. The inhibitory effects of LYP on the ES-2 xenografts were stronger than those of bestatin. These results suggest that LYP has a powerful inhibitory effect on the growth of OVCA cells and that the mechanism may be via a decrease in the expression of APN/CD13.


Aminopeptidase N (APN/CD13) Ovarian carcinoma (OVCA) LYP Bestatin Growth inhibition 



This project was supported by the Natural Science Foundation of China (30973550) and Shandong Provincial Foundation for Natural Science (Y2008C07). This work was also supported by Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Canada.


  1. 1.
    Mou J, Fang H, Jing F, Wang Q, Liu Y, Zhu H, Shang L, Wang X, Xu W (2009) Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem 17:4666–4673. doi: 10.1016/j.bmc.2009.04.056 PubMedCrossRefGoogle Scholar
  2. 2.
    Pérez I, Varona A, Blanco L, Gil J, Santaolalla F, Zabala A, Ibarguen AM, Irazusta J, Larrinaga G (2009) Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma. Head Neck 31:1335–1340. doi: 10.1002/hed.21099 PubMedCrossRefGoogle Scholar
  3. 3.
    Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C (2003) Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res 63:8500–8506PubMedGoogle Scholar
  4. 4.
    Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M (2008) Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl and alanyl-aminopeptidase inhibitors. Front Biosci 13:3699–3713. doi: org/10.2741/2960 PubMedCrossRefGoogle Scholar
  5. 5.
    Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis. Front Biosci 13:2356–2363. doi: org/10.2741/2849 PubMedCrossRefGoogle Scholar
  6. 6.
    Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97:652–659. doi: 10.1182/blood.V97.3.652 PubMedCrossRefGoogle Scholar
  7. 7.
    Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer 7:140. doi: 10.1186/1471-2407-7-140 PubMedCrossRefGoogle Scholar
  8. 8.
    Wulfaenger J, Niedling S, Riemann D, Seliger B (2008) Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion. Mol Membr Biol 25:72–82. doi: 10.1080/09687680701551855 PubMedCrossRefGoogle Scholar
  9. 9.
    Wang C, Fan G, Lin M, Chen Y, Zhao W, Wu Y (2007) Development of a liquid chromatography/tandem mass spectrometry assay for the determination of bestatin in rat plasma and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 850:101–108. doi: 10.1016/j.jchromb.2006.11.015 PubMedCrossRefGoogle Scholar
  10. 10.
    Yamashita M, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F (2007) Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. Int J Cancer 120:2243–2250. doi: 10.1002/ijc.22528 PubMedCrossRefGoogle Scholar
  11. 11.
    Xu Y, Lai LT, Gabrilove JL, Scheinberg DA (1998) Antitumor activity of actinonin in vitro and in vivo. Clin Cancer Res 4:171–176PubMedGoogle Scholar
  12. 12.
    Urabe A, Mutoh Y, Mizoguchi H, Takaku F, Ogawa N (1993) Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 67:63–66PubMedCrossRefGoogle Scholar
  13. 13.
    Luan YP, Wang XJ, Zhu HW, Qu XJ, Fang H, Xu WF (2009) The synthesis and activity evaluation of a bestatin derivative (LYP) as an aminopeptidase N inhibitor. Lett Drug Des Discov 6:420–423CrossRefGoogle Scholar
  14. 14.
    Chandrappa S, Benaka Prasad SB, Vinaya K, Ananda Kumar CS, Thimmegowda NR, Rangappa KS (2008) Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2, 4-diones. Invest New Drugs 26:437–444. doi: 10.1007/s10637-008-9130-7 PubMedCrossRefGoogle Scholar
  15. 15.
    Shahabuddin MS, Nambiar M, Choudhary B, Advirao GM, Raghavan SC (2010) A novel DNA intercalator, butylamino-pyrimido[4′, 5′:4, 5]selenolo(2, 3-b)quinoline, induces cell cycle arrest and apoptosis in leukemic cells. Invest New Drugs 28:35–48. doi: 10.1007/s10637-008-9212-6 PubMedCrossRefGoogle Scholar
  16. 16.
    Bauvois B, Puiffe ML, Bongui JB, Paillat S, Monneret C, Dauzonne D (2003) Synthesis and biological evaluation of novel flavone-8-acetic acid derivatives as reversible inhibitors of aminopeptidase N/CD13. J Med Chem 46:3900–3913. doi: 10.1021/jm021109f PubMedCrossRefGoogle Scholar
  17. 17.
    Qu XJ, Yang JL, Russell PJ, Goldstein D (2004) Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 172:733–738. doi: 10.1097/01.ju.0000130751.83953.55 PubMedCrossRefGoogle Scholar
  18. 18.
    Xiong X, Fu L, Wang L, Cai H, Li L, Jiang H, Duan W, Mei C (2009) Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Invest New Drugs 27:1–11. doi: 10.1007/s10637-008-9132-5 PubMedCrossRefGoogle Scholar
  19. 19.
    Liu J, Li X, Cheng YN, Cui SX, Chen MH, Xu WF, Tian ZG, Makuuchi M, Tang W, Qu XJ (2007) Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil. Eur J Pharmacol 574:1–7. doi: 10.1016/j.ejphar.2007.06.064 PubMedCrossRefGoogle Scholar
  20. 20.
    Okutucu B, Dincer A, Habib O, Zihnioglu F (2007) Comparison of five methods for determination of total plasma protein concentration. J Biochem Biophys Methods 70:709–711. doi: 10.1016/j.jbbm.2007.05.009 PubMedCrossRefGoogle Scholar
  21. 21.
    Wang SB, Cheng YN, Cui SX, Zhong JL, Ward SG, Sun LR, Chen MH, Kokudo N, Tang W, Qu XJ (2009) Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 26:469–477. doi: 10.1007/s10585-009-9246-y PubMedCrossRefGoogle Scholar
  22. 22.
    Fortin JP, Gera L, Bouthillier J, Stewart JM, Adam A, Marceau F (2005) Endogenous aminopeptidase N decreases the potency of peptide agonists and antagonists of the kinin B1 receptors in the rabbit aorta. J Pharmacol Exp Ther 314:1169–1176. doi: 10.1124/jpet.105.088799 PubMedCrossRefGoogle Scholar
  23. 23.
    Bauvois B, Dauzonne D (2006) Aminopeptidase-N/CD13 (EC inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 26:88–130. doi: 10.1002/med.20044 PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang X, Xu W (2008) Aminopeptidase N (APN/CD13) as a target for anti-cancer agent design. Curr Med Chem 15:2850–2865PubMedCrossRefGoogle Scholar
  25. 25.
    Jope RS, Jenden DJ (1979) Dimethylaminoethanol (deanol) metabolism in rat brain and its effect on acetylcholine synthesis. J Pharmacol Exp Ther 211:472–479PubMedGoogle Scholar
  26. 26.
    Haubrich DR, Gerber NH, Pflueger AB (1981) Deanol affects choline metabolism in peripheral tissues of mice. J Neurochem 37:476–482PubMedCrossRefGoogle Scholar
  27. 27.
    Sekine K, Fujii H, Abe F (1999) Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13:729–734PubMedCrossRefGoogle Scholar
  28. 28.
    Ito K, Nakajima Y, Onohara Y, Takeo M, Nakashima K, Matsubara F, Ito T, Yoshimoto T (2006) Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition. J Biol Chem 281:33664–33676. doi: 10.1074/jbc.M605203200 PubMedCrossRefGoogle Scholar
  29. 29.
    Xu W, Li Q (2005) Progress in the development of aminopeptidase N (APN/CD13) inhibitors. Curr Med Chem Anticancer Agents 5:281–301PubMedCrossRefGoogle Scholar
  30. 30.
    Luan Y, Xu W (2007) The structure and main functions of aminopeptidase N. Curr Med Chem 14:639–647PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jian-Jun Gao
    • 1
  • Zu-Hua Gao
    • 2
  • Cui-Rong Zhao
    • 1
  • Yi Yuan
    • 1
  • Shu-Xiang Cui
    • 3
  • Xiao-Fan Zhang
    • 1
  • Yan-Na Cheng
    • 1
  • Wen-Fang Xu
    • 1
  • Wei Tang
    • 1
  • Xian-Jun Qu
    • 1
    Email author
  1. 1.Department of Pharmacology, School of Pharmaceutical SciencesShandong UniversityJinanChina
  2. 2.Department of Pathology and Laboratory MedicineUniversity of Calgary and Calgary Laboratory ServicesCalgaryCanada
  3. 3.Department of Pharmacology, Institute of Materia MedicaShandong Academy of Medical SciencesJinanChina

Personalised recommendations